Overview
- Grifols reported a first‑half net profit of €227 million, a 28.7% increase, with adjusted EBITDA of €854 million and revenues of €3,574 million, a small year‑on‑year decline.
- The company completed a large refinancing that expanded a Term Loan B to about €3 billion and raised its revolving credit line to more than $2 billion, keeping leverage near 4.2x and prompting upgrades from S&P, Fitch and Moody's.
- Biopharma sales rose roughly 5.4%, driven by immunoglobulin products, while albumin revenue fell about 14% and Diagnostics declined about 9.7% after the early end of the QuidelOrtho joint business.
- Grifols is shifting plasma sourcing away from heavy U.S. dependence toward local collection in Egypt and Canada, a move that included closing some U.S. donation centres and produced transitional costs this quarter.
- The company reiterated full‑year targets and said the stronger cash flow and balance‑sheet position will support long‑term priorities, a development that follows earlier reputational and financial strains from the Gotham episode.